Recent News

• 03.16.2026 - iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
• 03.16.2026 - iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
• 03.09.2026 - iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
• 02.24.2026 - iBio to Participate in Upcoming Investor Conferences
• 02.10.2026 - iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
• 02.10.2026 - iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Recent Filings

• 03.09.2026 - EX-99.1 EX-99.1
• 03.09.2026 - 8-K Current report
• 03.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.06.2026 - EFFECT Notice of Effectiveness
• 02.27.2026 - 8-K Current report
• 02.27.2026 - S-3 Registration statement under Securities Act of 1933
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - 8-K Current report